A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia
Conditions:  Breast Cancer;  Prostate Cancer;  Pancreatic Cancer;  Acute Myelogenous Leukemia Interventions:  Procedure: Biopsy;  Drug: ABIRATERONE;  Drug: ENZALUTAMIDE;  Drug: VENETOCLAX;  Drug: PALBOCICLIB;  Drug: All-trans Retinoic Acid;  Drug: BORTEZOMIB;  Drug: CABAZITAXEL;  Drug: OXALIPLATIN;  Drug: FLUOROURACIL;  Drug: FOLINIC ACID;  Drug: CARBOPLATIN;  Drug : PANOBINOSTAT;  Drug: VORINOSTAT;  Drug: PEMBROLIZUMAB;  Drug: BEVACIZUMAB;  Drug: IPILIMUMAB;  Drug: NIVOLUMAB;  Drug: EVEROLIMUS;  Drug: SIROLIMUS;  Drug: CELECOXIB;  Drug: OLAPARIB;  Drug: AFATINIB;  Drug: CABOZANTINIB;  Drug: SORAFENIB;  Drug: DASATINIB;  Drug: ERLOTINIB;  Drug: IDELALISIB;  Drug: IMATINIB;  Drug: LENVATINIB;  Drug: PERTUZUMAB;  Drug: PONATINIB;  Drug: RUXOLITINIB;  Drug: SUNITINIB;  Drug: TRAMETINIB;  Drug: VEMURAFENIB Sponsors:  OHSU Knight Cancer Institute;  Oregon Health and Science University;  Prospect Creek Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Avastin | Cancer | Cancer & Oncology | Celebrex | Eloxatin | Gleevec | Leukemia | Pancreas | Pancreatic Cancer | Research | Study | Tarceva | Velcade | Yervoy